KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers

Journal of Surgical Oncology

Volumn 111, Issue 8, 2015, Pages 1059-1064

  Lee, Kyung Ha ^a   Kim, Jin Soo ^a   Lee, Choong Sik ^a   Kim, Ji Yeon ^a  

^a Chungnam National University College of Medicine   (South Korea)

Author keywords

colorectal neoplasms; KRAS protein; neoplasm metastasis

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

AGED; COLORECTAL NEOPLASMS; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84934437988     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23936     Document Type: Article

References (46)

1. Van Cutsem E, Kohne CH, Lang I, et al.,: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2010; 29: 2011-2019.
2. Bokemeyer C, Bondarenko I, Hartmann JT, et al.,: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26: 4000.
3. Baldus SE, Schaefer KL, Engers R, et al.,: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-799.
4. Watanabe T, Kobunai T, Yamamoto Y, et al.,: Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 2011; 54: 1170-1178.
5. Scaltriti M, Baselga J,: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
6. Barault L, Veyrie N, Jooste V, et al.,: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008; 122: 2255-2259.
7. Khambata-Ford S, Garrett CR, Meropol NJ, et al.,: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
8. Amado RG, Wolf M, Peeters M, et al.,: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
9. Karapetis CS, Khambata-Ford S, Jonker DJ, et al.,: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
10. Fearon ER, Vogelstein B,: A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
11. Vogelstein B, Fearon ER, Hamilton SR, et al.,: Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
12. Rajagopalan H, Bardelli A, Lengauer C, et al.,: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
13. Hermsen M, Postma C, Baak J, et al.,: Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology 2002; 123: 1109-1119.
14. Losi L, Benhattar J, Costa J,: Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 1992; 28A: 1115-1120.
15. Melucci E, Conti S, Diodoro M, et al.,: Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer. J Clin Oncol 2010; 28: 3568.
16. Italiano A, Hostein I, Soubeyran I, et al.,: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications. Ann Surg Oncol 1429; 17: 1434.
17. Cejas P, Lopez-Gomez M, Aguayo C, et al.,: KRAS mutations in primary colorectal cancer tumors and related metastases: A potential role in prediction of lung metastasis. PLoS One 2009; 4: e8199.
18. Molinari F, Martin V, Saletti P, et al.,: Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 2009; 100: 1087-1094.
19. Loupakis F, Pollina L, Stasi I, et al.,: PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-2629.
20. Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al.,: The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009; 20: 879-884.
21. Etienne-Grimaldi MC, Formento JL, Francoual M, et al.,: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008; 14: 4830-4835.
22. Zauber P, Sabbath-Solitare M, Marotta SP, et al.,: Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas. Mol Pathol 2003; 56: 137-140.
23. Schimanski CC, Linnemann U, Berger MR,: Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 1999; 59: 5169-5175.
24. Al-Mulla F, Going JJ, Sowden ET, et al.,: Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 1998; 185: 130-138.
25. Finkelstein SD, Sayegh R, Christensen S, et al.,: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993; 71: 3827-3838.
26. Suchy B, Zietz C, Rabes HM,: K-ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis. Int J Cancer 1992; 52: 30-33.
27. Oudejans JJ, Slebos RJ, Zoetmulder FA, et al.,: Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991; 49: 875-879.
28. Artale S, Sartore-Bianchi A, Veronese SM, et al.,: Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-4219.
29. Santini D, Loupakis F, Vincenzi B, et al.,: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 2008; 13: 1270-1275.
30. Knijn N, Mekenkamp LJ, Klomp M, et al.,: KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104: 1020-1026.
31. Vakiani E, Janakiraman M, Shen R, et al.,: Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30: 2956-2962.
32. Tortola S, Steinert R, Hantschick M, et al.,: Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 2001; 19: 2837-2843.
33. Mostert B, Jiang Y, Sieuwerts AM, et al.,: KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013; 133: 130-141.
34. Gerlinger M, Rowan AJ, Horswell S, et al.,: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
35. Richman SD, Chambers P, Seymour MT, et al.,: Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011; 34: 61-66.
36. Losi L, Baisse B, Bouzourene H, et al.,: Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005; 26: 916-922.
37. Albanese I, Scibetta AG, Migliavacca M, et al.,: Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. Biochem Biophys Res Commun 2004; 325: 784-791.
38. Poste G, Fidler IJ,: The pathogenesis of cancer metastasis. Nature 1980; 283: 139-146.
39. Nowell PC,. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
40. Richman SD, Chambers P, Seymour MT, et al.,: Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011; 34: 61-66.
41. Klein CA,. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-312.
42. Kim MJ, Lee HS, Kim JH, et al.,: Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 2012; 12: 347.
43. Tie J, Lipton L, Desai J, et al.,: KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 2011; 17: 1122-1130.
44. De Roock W, Claes B, Bernasconi D, et al.,: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
45. Stintzing S, Fischer von Weikersthal L, Decker T, et al.,: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: Mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol 2012; 23: 1693-1699.
46. Baas JM, Krens LL, Guchelaar HJ, et al.,: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review. Oncologist 2011; 16: 1239-1249.